Login
$NKTR
$36.29 -$0.15 (0.41%) After hours

$NKTR SEC Filings

Filed On Filing
13 Nov 2026 8-K: Regulation FD Disclosure

In conjunction with its third quarter financial results announced yesterday, November 12, 2026, Nektar Therapeutics (the “Company”) reported $952.9 million in cash and investments in marketable securities as of September 30, 2026. Consis...

13 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

SAN FRANCISCO, November 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

10 Nov 2026 SCHEDULE 13G
20 Oct 2026 REGISTRATION STATEMENT
01 Oct 2026 8-K: Regulation FD Disclosure

Forward-Looking Statements 2 Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not ...

28 Sep 2026 SCHEDULE 13G/A
25 Sep 2026 Form 4: Whitfield Roy A, Director

Received 2,000 shares as a grant or award · Granted 4,000 Stock Option

25 Sep 2026 Form 4: Greer R Scott, Director

Received 2,000 shares as a grant or award · Granted 4,000 Stock Option

25 Sep 2026 Form 4: Chess Robert, Director

Received 2,000 shares as a grant or award · Granted 4,000 Stock Option

25 Sep 2026 Form 4: Brainard Diana, Director

Received 2,000 shares as a grant or award · Granted 4,000 Stock Option

25 Sep 2026 Form 4: Ajer Jeffrey Robert, Director

Received 2,000 shares as a grant or award · Granted 4,000 Stock Option

25 Sep 2026 8-K: Other Events

In August 2023, Nektar Therapeutics (the “Company”) filed a complaint in the U.S. District Court for the Northern District of California (the “District Court”) against Eli Lilly and Company (“Lilly”) alleging, among other claims, breach ...

08 Sep 2026 8-K: Regulation FD Disclosure

Nektar Therapeutics (the “Company”) is entering a quiet period beginning September 8, 2026 and continuing until the public announcement of data from the 24-week off treatment follow-up period of its Phase 2b REZOLVE-AA study of rezpegald...

20 Aug 2026 Form 4: Zalevsky Jonathan, Chief R&D Officer

Sold 186 shares ($13.4K)

20 Aug 2026 Form 4: Robin Howard W, Director

Sold 418 shares ($30.1K)

18 Aug 2026 144
18 Aug 2026 144
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support